

REMARKS

In the present Action, claims 1-7, 9-22 and 24-53 are pending. Claims 3 and 23 were canceled and claims 9-18 and 30-45 were withdrawn. In this supplemental response, Applicants have amended claim 19 to recite a generic shuttle expression vector for the construction and screening of the single chain monoclonal antibody reagent. In addition, Applicants have added a new vector claim 54 that is dependent on amended claim 19 and directed to a pVP16Zeo expression vector. Support for this amendment is found in the specification at page 22, lines 10 and page 31, lines 8-9. Upon entry of this amendment, claims 1-7, 19-22, 24-29, 46-54 will be pending for examination on the merits.

A detailed listing of all claims that are, or were, in the application, irrespective of whether the claim(s) remain under examination in the application, are presented with an appropriate defined status identifier. The amendment does not go beyond the original disclosure of the application.

In accordance with the foregoing, examination on the merits is requested. Should there be any questions or should the Examiner wish to discuss any proposal to expedite prosecution, the Examiner is invited to contact the undersigned representative at the telephone number shown below.

If there are any fees due in connection with the filing of this response, please charge the fees to Deposit Account No. 19-0741.

Respectfully submitted,

Date 14 August 2003

By S. A. Bent

FOLEY & LARDNER
Customer Number: 22428



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5404

Facsimile: (202) 672-5399

Stephen A. Bent
Attorney for Applicant
Registration No. 29,768